A 2023 mouse study reignited interest in an amino acid most people associate with energy drinks. Here is what the data shows, what it doesn't, and why Geroevidence hasn't assigned it an evidence tier yet.
Taurine levels decline with age across species. A 2023 study asked whether restoring them extends lifespan.
Taurine is a sulfur-containing amino acid synthesized endogenously and obtained from the diet, long associated with energy drink formulations and largely overlooked in longevity research. That changed with Singh and colleagues' 2023 publication reporting that circulating taurine levels decline with age in mice, monkeys, and humans, and that taurine supplementation extended lifespan in mouse models. The finding repositioned taurine, almost overnight, from a supplement-aisle ingredient to a compound with a genuine geroscience research question behind it.
The 2023 study reported that taurine supplementation extended mouse lifespan and improved several markers of healthy aging, alongside the observation that taurine levels decline with age across multiple species, including humans. This is mouse lifespan data, not human outcome data — an important distinction, since many compounds that extend lifespan in mice (rapamycin and 17α-estradiol among them, via the NIA's Interventions Testing Program) do not automatically translate to confirmed human benefit, and some compounds with promising mouse data have failed to replicate in subsequent human trials.
Human trial data specific to taurine's longevity effects is still emerging. Taurine itself has a long history of use as a dietary supplement, generally considered to have a favorable safety profile at studied doses — but a long safety record for a supplement is not the same as a validated longevity outcome trial. This is the gap Geroevidence's evidence-tier system is designed to make visible rather than obscure: a compound can have a compelling mechanistic story and strong animal data while genuinely lacking the human trial base needed for a Moderate or Strong rating.
Geroevidence assigns a formal evidence tier once a minimum threshold is met — at least one published human trial, or strong Interventions Testing Program-style lifespan data. Taurine's current profile sits under editorial review rather than at a tier, an accurate reflection of where the evidence base stands today: a genuinely interesting mouse-to-human translational question, not yet a validated human intervention.
As human trial data accumulates, Geroevidence will update the taurine profile and assign a tier once the threshold is met — the same standard applied across every compound tracked on the platform.